EMA accepts Merck and ARIAD's MAA for ridaforolimus to treat metastatic bone sarcomas
Links shared publicly online about this topic.
- 63total visits
EMA accepts Merck and ARIAD's MAA for ridaforolimus to treat metastatic bone sarcomas
Merck, known outside the United States and Canada as MSD, and ARIAD Pharmaceuticals, Inc., today announced that the European Medicines Agency (EMA) has completed its administrative validation process for the regulatory application for ridaforolimus, an investigational oral mTOR inhibitor developed for the treatment of metastatic soft-tissue or bone sarcomas in patients who had a favorable response to chemotherapy.
View full resource at news-medical.net
Tags: Cancer, Bone, Pharma, Merck & Co., Oncology, News, Medicine
Most Recently Shared on August 18, 2011 at 6:26 pm By:
Oncology News: EMA accepts Merck and ARIAD's MAA for ridaforolimus to treat metastatic bone sarcomas: Merck, kno... http://t.co/cybu5NQ
Advertisement
